At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAMS NEWAMSTERDAM PHARMA CO NV
Trading 04-02 12:08:21 EDT
18.48
+0.10
+0.52%
| High18.53 | Low17.64 | Vol548.38K |
| Open18.50 | D1 Closing18.38 | Amplitude4.87% |
| Mkt Cap2.03B | Tradable Cap996.57M | Total Shares109.82M |
| T/O10.00M | T/O Rate1.02% | Tradable Shares53.94M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TIPRANKS · 04-01 10:46
William Blair Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TIPRANKS · 04-01 02:45
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire · 03-31 12:00
NewAmsterdam Pharma Company Nv : Guggenheim Raises Target Price to $41 From $35
THOMSON REUTERS · 03-03
NewAmsterdam Pharma files $500M mixed securities shelf
TIPRANKS · 02-28
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Organogenesis Holdings (ORGO)
TIPRANKS · 02-28
NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. · 02-27
NewAmsterdam Pharma Is Maintained at Buy by Needham
Dow Jones · 02-27
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence
TIPRANKS · 02-27
NewAmsterdam Pharma Company (NAMS) Receives a Buy from William Blair
TIPRANKS · 02-26
NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises
MT Newswires Live · 02-26
Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M
MT Newswires Live · 02-26
Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Net Loss of $241.6M
MT Newswires Live · 02-26
NewAmsterdam Pharma FY24 Sales $45.6M Beats $31.982M Estimate
Benzinga · 02-26
Press Release: NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
Dow Jones · 02-26
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
GlobeNewswire · 02-25
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease
Simply Wall St. · 02-14
Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 02-07
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
Blockhead · 01-31
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
GlobeNewswire · 01-29
Introduction
Company Name.
NEWAMSTERDAM PHARMA CO NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App